Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229550382> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4229550382 endingPage "A32" @default.
- W4229550382 startingPage "A32" @default.
- W4229550382 abstract "82 Background: We have previously reported at our Phase I study that prolonged low dose IL-2 (Proleukin™) therapy is well tolerated and immunomodulatory in patients (pts) with AIDS malignancies. We have completed and are now reporting on our Phase II study. Methods: Entrants received daily SQ injection of low dose recombinant rIL-2 (Proleukin) for 90 consecutive days at the previously established maximum tolerated dose (MTD) of 1.2×106 U/m2 qd in pts with complete remission (CR) or stable disease (SD) at entry. After 21 days off study, pts could be re-entered to receive additional courses of therapy. Thirty-seven courses were administered to 22 pts. Six courses were non-evaluable due to non-compliance. An additional 5 courses were reduced to .9×106 U/m2 due to grade 3 toxicity (lethargy and myalgias). One of these individuals was able to tolerate the MTD on her 2nd course. Disease responses for evaluable courses are summarized below. TableThe pt who has been on study for the longest period of time (4 courses), has responded to IL-2 with complete resolution of his residual lymphoma. Immunologic analysis reveals a statistically significant expansion of NK cells as noted in the previous Phase I study and no appreciable change in CD4+, CD8+ cells, naive or memory T-cells. No opportunistic infections have been observed while pts were on study. Serial quantification of plasma HIV load by PCR analysis of Particle-Associated HIV-1 gag RNA copies has not revealed any significant change in viral titer. The data suggest that prolonged rIL-2 therapy at a dose of 1.2×106 U/m2/day is well tolerated in this population and appears to be effective in maintaining disease response in individuals with lymphoma." @default.
- W4229550382 created "2022-05-11" @default.
- W4229550382 creator A5001226520 @default.
- W4229550382 creator A5012801529 @default.
- W4229550382 creator A5019624678 @default.
- W4229550382 creator A5038434433 @default.
- W4229550382 creator A5052252975 @default.
- W4229550382 creator A5071914151 @default.
- W4229550382 creator A5073385727 @default.
- W4229550382 date "1998-04-01" @default.
- W4229550382 modified "2023-09-27" @default.
- W4229550382 title "A PHASE II STUDY OF DAILY SUBCUTANEOUS (SQ) LOW DOSE INTERLEUKIN-2 (IL-2), IN HIV-ASSOCIATED MALIGNANCIES." @default.
- W4229550382 doi "https://doi.org/10.1097/00042560-199804010-00097" @default.
- W4229550382 hasPublicationYear "1998" @default.
- W4229550382 type Work @default.
- W4229550382 citedByCount "1" @default.
- W4229550382 crossrefType "journal-article" @default.
- W4229550382 hasAuthorship W4229550382A5001226520 @default.
- W4229550382 hasAuthorship W4229550382A5012801529 @default.
- W4229550382 hasAuthorship W4229550382A5019624678 @default.
- W4229550382 hasAuthorship W4229550382A5038434433 @default.
- W4229550382 hasAuthorship W4229550382A5052252975 @default.
- W4229550382 hasAuthorship W4229550382A5071914151 @default.
- W4229550382 hasAuthorship W4229550382A5073385727 @default.
- W4229550382 hasBestOaLocation W42295503821 @default.
- W4229550382 hasConcept C126322002 @default.
- W4229550382 hasConcept C167672396 @default.
- W4229550382 hasConcept C203014093 @default.
- W4229550382 hasConcept C2522874641 @default.
- W4229550382 hasConcept C2777260799 @default.
- W4229550382 hasConcept C2779338263 @default.
- W4229550382 hasConcept C29730261 @default.
- W4229550382 hasConcept C31760486 @default.
- W4229550382 hasConcept C32611913 @default.
- W4229550382 hasConcept C71924100 @default.
- W4229550382 hasConcept C8891405 @default.
- W4229550382 hasConcept C90924648 @default.
- W4229550382 hasConceptScore W4229550382C126322002 @default.
- W4229550382 hasConceptScore W4229550382C167672396 @default.
- W4229550382 hasConceptScore W4229550382C203014093 @default.
- W4229550382 hasConceptScore W4229550382C2522874641 @default.
- W4229550382 hasConceptScore W4229550382C2777260799 @default.
- W4229550382 hasConceptScore W4229550382C2779338263 @default.
- W4229550382 hasConceptScore W4229550382C29730261 @default.
- W4229550382 hasConceptScore W4229550382C31760486 @default.
- W4229550382 hasConceptScore W4229550382C32611913 @default.
- W4229550382 hasConceptScore W4229550382C71924100 @default.
- W4229550382 hasConceptScore W4229550382C8891405 @default.
- W4229550382 hasConceptScore W4229550382C90924648 @default.
- W4229550382 hasIssue "4" @default.
- W4229550382 hasLocation W42295503821 @default.
- W4229550382 hasLocation W42295503822 @default.
- W4229550382 hasOpenAccess W4229550382 @default.
- W4229550382 hasPrimaryLocation W42295503821 @default.
- W4229550382 hasRelatedWork W2038814830 @default.
- W4229550382 hasRelatedWork W2048342976 @default.
- W4229550382 hasRelatedWork W2049552282 @default.
- W4229550382 hasRelatedWork W2070741059 @default.
- W4229550382 hasRelatedWork W2088492088 @default.
- W4229550382 hasRelatedWork W2368674520 @default.
- W4229550382 hasRelatedWork W2421671780 @default.
- W4229550382 hasRelatedWork W330609278 @default.
- W4229550382 hasRelatedWork W2600016689 @default.
- W4229550382 hasRelatedWork W2652274754 @default.
- W4229550382 hasVolume "17" @default.
- W4229550382 isParatext "false" @default.
- W4229550382 isRetracted "false" @default.
- W4229550382 workType "article" @default.